CRISPR_Logo.jpg
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
May 06, 2021 16:01 ET | CRISPR Therapeutics AG
-Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities- -Companies to co-develop...
CRISPR_Logo.jpg
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
April 29, 2021 08:30 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR_Logo.jpg
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
April 28, 2021 16:01 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR_Logo.jpg
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
April 27, 2021 16:01 ET | CRISPR Therapeutics AG
- Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)- -More than 30 patients have been dosed with CTX001 across...
CRISPR_Logo.jpg
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
April 26, 2021 08:30 ET | CRISPR Therapeutics AG
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) --  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the...
CRISPR_Logo.jpg
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program...
CRISPR_Logo.jpg
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
April 10, 2021 08:31 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR_Logo.jpg
CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 08:00 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR_Logo.jpg
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
March 10, 2021 17:03 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR_Logo.jpg
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
March 03, 2021 08:00 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...